BioMarin Pharmaceutical Inc. (BMRN) Announces Phase 1 Results for BMN-111 for Achondroplasia  
9/27/2012 10:11:28 AM

NOVATO, Calif., Sept. 26, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the completion of a Phase 1 study for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia. The company expects to initiate a Phase 2 trial in mid-2013.